Comparison of current US risk strategy to screen for hepatitis C virus with a hypothetical targeted birth cohort strategy

American Journal of Public Health

Volumn 102, Issue 11, 2012, Pages

  Tomaszewski, Kenneth J ^a   Deniz, Baris ^b   Tomanovich, Peter ^a   Graham, Camilla S ^b  

^a KJT Group   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; AGE; AGED; ARTICLE; BLOOD; COMPARATIVE STUDY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; PRACTICE GUIDELINE; RISK FACTOR; UNITED STATES;

ADULT; AGE FACTORS; AGED; ALANINE TRANSAMINASE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84867508414     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2011.300488     Document Type: Article

References (29)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705-714.
2. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513-521.
3. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341 (8):556-562.
4. Colvin HM, Mitchell AE. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: National Academies Press; 2010.
5. Pyenson BS, Fitch K, Iwasaki K. Consequences of Hepatitis C Virus (HCV): Costs of a Baby Boomer Epidemic of Liver Disease. New York, NY; 2009.
6. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50(6):1750-1755.
7. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418-431.
8. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-1374.
9. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345(1):41-52.
10. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology. 2006;43(6):1303-1310.
11. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47(RR-19):1-39.
12. NIH consensus statement on management of hepatitis C. NIH Consens State Sci Statements. 2002;19(3):1-46.
13. Shatin D, Schech SD, Patel K, McHutchison JG. Population-based hepatitis C surveillance and treatment in a national managed care organization. Am J Manag Care. 2004;10(4):250-256.
14. Roblin DW, Smith BD, Weinbaum CM, Sabin ME. HCV screening practices and prevalence in an MCO, 2000-2007. Am J Manag Care. 2011;17(8):548-555.
15. McHutchison JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. Am J Manag Care. 2005;11 (10 suppl):S286-S295; quiz S307-S311.
16. Shehab TM, Orrego M, Chunduri R, Lok AS. Identification and management of hepatitis C patients in primary care clinics. Am J Gastroenterol. 2003;98 (3):639-644.
17. Shehab TM, Sonnad SS, Lok AS. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. J Viral Hepat. 2001;8 (5):377-383.
18. Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002;36(5 suppl 1):S30-S34.
19. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-982.
20. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358 (9286):958-965.
21. Kronenberger B, Welsch C, Forestier N, Zeuzem S. Novel hepatitis C drugs in current trials. Clin Liver Dis. 2008;12(3):529-555, viii.
22. Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. Hepatology. 2006;43(2 suppl 1): S207-S220.
23. Sulkowski MS. Specific targeted antiviral therapy for hepatitis C. Curr Gastroenterol Rep. 2007;9(1):5-13.
24. INCIVEK [US Prescribing Information]. Cambridge, MA: Vertex Pharmaceuticals Inc; 2012.
25. VICTRELIS [US Prescribing Information]. Whitehouse Station, NJ: Merck; 2011.
26. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52 (3):833-844.
27. Mitchell AE, Colvin HM, Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology. 2010;51 (3):729-733.
28. Edlin BR. Five million Americans infected with the hepatitis C virus: a corrected estimate. Hepatology. 2005;42(4 suppl 1):213.
29. Velez F, Deniz B, Aggarwal S. Review of chronic hepatitis C management in correctional facilities in the United States. Paper presented at: National Conference on Correctional Health Care; Las Vegas, NV; October 10, 2010.